Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AJ Complement inhibitors
L04AJ08 Iptacopan
D12252 Iptacopan hydrochloride (USAN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
Complement Inhibitors
Iptacopan
D12252 Iptacopan hydrochloride (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D12252 Iptacopan hydrochloride (USAN); Iptacopan hydrochloride hydrate (JAN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG03207 Iptacopan
D12252 Iptacopan hydrochloride
DG01644 CYP2D6 substrate
DG03207 Iptacopan
D12252 Iptacopan hydrochloride
DG02924 UGT substrate
DG03183 UGT1A1 substrate
DG03207 Iptacopan
D12252 Iptacopan hydrochloride
DG03184 UGT1A3 substrate
DG03207 Iptacopan
D12252 Iptacopan hydrochloride
DG03186 UGT1A8 substrate
DG03207 Iptacopan
D12252 Iptacopan hydrochloride
Target-based classification of drugs [BR:br08310]
Peptidases and inhibitors
Serine peptidases
Chymotrypsin family
CFB
D12252 Iptacopan hydrochloride (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D12252
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D12252
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D12252
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12252
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D12252
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG03207 Iptacopan
DG01644 CYP2D6 substrate
DG03207 Iptacopan
DG02924 UGT substrate
DG03183 UGT1A1 substrate
DG03207 Iptacopan
DG03184 UGT1A3 substrate
DG03207 Iptacopan
DG03186 UGT1A8 substrate
DG03207 Iptacopan